Celldex/$CLDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Ticker
$CLDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
186
ISIN
US15117B2025
Website
Celldex Metrics
BasicAdvanced
$1.4B
-
-$2.70
1.39
-
Price and volume
Market cap
$1.4B
Beta
1.39
52-week high
$46.86
52-week low
$14.40
Average daily volume
980K
Financial strength
Current ratio
21.668
Quick ratio
21.029
Long term debt to equity
0.274
Total debt to equity
0.488
Management effectiveness
Return on assets (TTM)
-16.88%
Return on equity (TTM)
-23.20%
Valuation
Price to revenue (TTM)
178.418
Price to book
1.92
Price to tangible book (TTM)
2.04
Price to free cash flow (TTM)
-7.78
Growth
Revenue change (TTM)
24.49%
Earnings per share change (TTM)
-4.32%
3-year revenue growth (CAGR)
22.22%
3-year earnings per share growth (CAGR)
16.09%
What the Analysts think about Celldex
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Celldex Financial Performance
Revenues and expenses
Celldex Earnings Performance
Company profitability
Celldex News
AllArticlesVideos
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
GlobeNewsWire·8 hours ago
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
GlobeNewsWire·2 days ago
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
GlobeNewsWire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $1.4B as of June 13, 2025.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of June 13, 2025.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.